COVID-19 Business Intelligence and Analysis for Clinical Laboratories, Pathology Groups and Hospital Administration

COVID-19 Briefings

Reliable COVID-19 Business Intelligence and analysis for clinical laboratories, pathology groups and Laboratory Diagnostics.

Regulatory Agencies Are Investigating and Prosecuting COVID-19 Related Fraud and Waste

Share on facebook
Share on twitter
Share on linkedin
Share on pinterest
Share on whatsapp
Share on email
Share on facebook
Share on twitter
Share on linkedin
Share on google
Share on whatsapp
Share on email

Clinical labs must pay attention to regulatory rules during the COVID-19 pandemic.

Federal and state regulatory agencies are already starting to investigate and prosecute fraud and abuse of COVID-19 testing and treatment. Clinical laboratories and pathology groups should be aware of these recent activities and ensure that their activities are compliant with statutes such as Eliminating Kickbacks in Recovery Act of 2018 (EKRA) and Anti-Kickback Statute (AKS).

Recent areas being focused on by regulatory agencies include the following:

  • The advertisement of treatments and tests that have not been proven or authorized
  • Arranging and paying for kickbacks as compensation for referrals to clinical laboratories
  • Encouraging or performing COVID-19 testing that is medically unnecessary
  • Marking activities that target Medicare beneficiaries

An individual from Georgia was charged by U.S. Attorney’s Office for the District of New Jersey on March 30, 2020, for arranging a COVID-19 related kickback scheme. In this scheme, the individual allegedly arranged to obtain kickbacks on a per-test basis and have them bundled with a much more expensive respiratory pathogen panel (RPP) test.

Clinical laboratories can avoid regulatory issues by ensuring that each test billed has a valid medical order. Medical necessity rules will still apply, even in a regulatory environment that may seem more relaxed in some ways.

Clinical labs should also consider evaluating their marketing relationships and ensuring that marketing compensation is not related to testing volumes. Labs that work with independent marketing firms should be especially conscientious that all AKS, EKRA, and state anti-kickback laws are being followed.

Craig Carpenito, U.S. Attorney for the District of New Jersey


Helping Your Lab Stay Afloat During Challenging Times

Dear Colleague,

Robert L. MichelIn these challenging times for our colleagues in clinical laboratories, pathology practices and hospital administration, The Dark Intelligence Group (TDIG) — through generous grants from our partners — is bringing you the COVID-19 STAT Intelligence Briefings.

We’ve added analysts, writers and skilled editors to the COVID-19 STAT team to uncover, analyze, and immediately report to you what’s happening with the SARS-CoV-2 pandemic, packaged with the insights you need to deliver quality testing for patient care and keep your lab’s financial ship afloat. As part of our mission, we are also bringing you real-time data from our partners around testing that you will not find anywhere else.

Please let me know how we can better improve this service to fit your needs. If you would like to offer a grant to keep our mission going with this site, please contact me at


Robert L. Michel
President, Founder
The Dark Intelligence Group